Israeli multinational pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on Monday announced final results from its pan-European PEARL Phase 4 observational study, confirming the sustained effectiveness of AJOVY (fremanezumab) in preventing chronic and episodic migraine over 24 months.

Fremanezumab achieved consistent reductions in migraine frequency, duration, and severity. Data confirmed that both primary and secondary endpoints were met, with injection adherence of approximately 90% and over 75% of patients completing the study.

The PEARL study included 1,140 patients, predominantly female (87.2%), with 33.1% experiencing episodic migraine and 66.9% chronic migraine. Participants tracked migraine activity daily while receiving regular doses of fremanezumab. Among those achieving a 50% or greater reduction in monthly migraine days during the first six months, over 66% with episodic migraine and 51.6% with chronic migraine maintained this reduction for more than 24 months.

Investigators also reported that fremanezumab maintained a favourable long-term safety and tolerability profile consistent with earlier analyses. These findings support the continued clinical use of fremanezumab and highlight the role of real-world data in guiding treatment decisions.

AJOVY is indicated for the prevention of migraine in adults with at least four migraine days per month and is delivered via subcutaneous injection as either a monthly or quarterly dosing regimen.